Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
15 06 2020
Historique:
received: 05 07 2019
revised: 06 12 2019
accepted: 24 02 2020
pubmed: 29 2 2020
medline: 11 11 2020
entrez: 29 2 2020
Statut: ppublish

Résumé

Because of the high coverage of international vaccination programs, most people worldwide have been vaccinated against common pathogens, leading to acquired pathogen-specific immunity with a robust memory T-cell repertoire. Although CD8

Identifiants

pubmed: 32107211
pii: 0008-5472.CAN-19-2062
doi: 10.1158/0008-5472.CAN-19-2062
doi:

Substances chimiques

Antigens, Neoplasm 0
Antineoplastic Agents, Immunological 0
Cancer Vaccines 0
DTPP vaccine 0
Diphtheria-Tetanus-Pertussis Vaccine 0
Histocompatibility Antigens Class I 0
Histocompatibility Antigens Class II 0
Pdcd1 protein, mouse 0
Poliovirus Vaccine, Inactivated 0
Programmed Cell Death 1 Receptor 0
Vaccines, Combined 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2575-2585

Subventions

Organisme : European Research Council
ID : 681219
Pays : International

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Siri Tähtinen (S)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Sara Feola (S)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Cristian Capasso (C)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Netta Laustio (N)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Christianne Groeneveldt (C)

Faculty of Science, Leiden University, Leiden, the Netherlands.

Erkko O Ylösmäki (EO)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Leena Ylösmäki (L)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Beatriz Martins (B)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Manlio Fusciello (M)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Marta Medeot (M)

Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Padova, Italy.

Maria Tagliamonte (M)

Cancer Immunoregulatory, Istituto Nazionale Tumori (IRCCS) G. Pascale, Naples, Italy.

Jacopo Chiaro (J)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Firas Hamdan (F)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Karita Peltonen (K)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland.

Tuuli Ranki (T)

ValoTherapeutics, Helsinki, Finland.

Luigi Buonaguro (L)

Cancer Immunoregulatory, Istituto Nazionale Tumori (IRCCS) G. Pascale, Naples, Italy.

Vincenzo Cerullo (V)

Drug Research Program ImmunoViroTherapy Lab (IVT), Faculty of Pharmacy iCAN Digital Precision Cancer Medicine Flagship, Helsinki University, Viikinkaari 5E, Finland. vincenzo.cerullo@helsinki.fi.
Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
Department of Molecular Medicine and Medical Biotechnology, Naples University "Federico II", Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH